To assess the value and timing of percutaneous transluminal coronary angioplasty (PTCA)
after thrombolytic therapy for acute myocardial infarction (AMI), 586 patients in the …

This report describes the organization and results of the European Cooperative Study Group
trial of intravenous recombinant tissue-type plasminogen activator (rt-PA) plus conservative …

Clot dissolution with restoration of infarct-related artery blood flow is the likely mechanism for
the improved prognosis and mortality reduction seen after thrombolytic therapy of acute …

Objectives. Our aim was to design and evaluate a new and easily administered recombinant
tissue-type plasminogen activator (rt-PA) regimen for thrombolysis in acute myocardial …

The novel recombinant plasminogen activator (rPA)(BM 06.022) is a mutant of tissue-type
plasminogen activator expressed in escherichia coli which can be given as a bolus because …

The hypothesis that an infusion of recombinant tissue-type plasminogen activator (rt-PA)
maintained for up to 24 hours could prevent reocclusion after early coronary patency had …

Objectives. The present study was designed to test the efficacy and safety of a sequential
combination of recombinant tissue-type plasminogen activator (rt-PA) and pro-urokinase in …

Thrombolytic therapy has been shown to reduce mortality and morbidity after acute
myocardial infarction. Therapeutic benefit seems to be directly correlated with completeness …

Numerous controlled clinical trials have documented the efficacy of thrombolytic agents in
reducing the risk of mortality after myocardial infarction (MI). As a result, it is no longer ethical …

The effects of recombinant tissue plasminogen activator (rt-PA) and urokinase on patency
and early reocclusion of infarct-related coronary arteries were investigated in a single blind …